In ALL cells, PON2 silencing promotes caspase-3 activity and apoptosis following DEX treatment, complemented by a drop in Bcl-2 and an upsurge in Bax expression (Hui et al. 2022). This evidence concerns the gene BCL2 and acute lymphoblastic leukemia.